Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Phase II Conjugation Reactions: Overview01:14

Phase II Conjugation Reactions: Overview

1.2K
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
1.2K
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

117
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
117
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

113
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
113
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

11.7K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional Characterisation of NF-YCs in True Leaf Biomass Accumulation.

Plants (Basel, Switzerland)·2026
Same author

Sex- and age-dependent physiological adaptation of captive père david's deer revealed by multi-omics analysis.

BMC genomics·2026
Same author

Correction to "Triphase Interface Synthesis of Plasmonic Gold Bellflowers as Near-Infrared Light Mediated Acoustic and Thermal Theranostics".

Journal of the American Chemical Society·2026
Same author

Instance-dependent Early Stopping for Adaptive Data Pruning.

IEEE transactions on pattern analysis and machine intelligence·2026
Same author

Genome-Wide Analysis of the <i>KNOX</i> Gene Family in <i>Malus sieversii</i>.

Plants (Basel, Switzerland)·2026
Same author

Quantifying intrafractional colon tumor motion on 1.5 T MR-linac cine-MRI and applying anisotropic residual-motion margins for SBRT.

Radiation oncology (London, England)·2026
Same journal

Iron Single Atom Nanozyme-Mediated GPX4 Inhibitor Delivery for Self-Enhanced Ferroptosis.

Bioconjugate chemistry·2026
Same journal

SpyCatcher-Engineered Ferritin Nanocages Enable Dual-Receptor Targeting for Enhanced Glioma Therapy.

Bioconjugate chemistry·2026
Same journal

One-Pot Synthesis of Functionalized Coumarin Fluorophores Enables Rapid Access to Live-Cell Bioorthogonal Labeling and Microenvironmental Sensing Agents.

Bioconjugate chemistry·2026
Same journal

Enzymatic Synthesis of Glyco-DNA Equipped with Oligosaccharides and Charged Monosaccharides.

Bioconjugate chemistry·2026
Same journal

Electrochemical Tryptophan-Selective Bioconjugation in Neutral Buffer via Cooperative <i>N</i>-Oxyl Radicals.

Bioconjugate chemistry·2026
Same journal

Conjugates of Heme and Intrinsically Disordered Peptides toward the Development of Synthetic Artificial Oxygen Carriers.

Bioconjugate chemistry·2026
See all related articles

Related Experiment Video

Updated: Apr 9, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.6K

Aptamer-Drug Conjugates.

Guizhi Zhu1, Gang Niu1, Xiaoyuan Chen1

  • 1Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health , Bethesda, Maryland 20892, United States.

Bioconjugate Chemistry
|June 18, 2015
PubMed
Summary
This summary is machine-generated.

Aptamer-drug conjugates (ApDCs) offer targeted therapy by using aptamers, or chemical antibodies, to guide drugs to diseased cells. This approach enhances treatment selectivity and reduces side effects in various therapies, including cancer treatment.

More Related Videos

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.3K
Aptamer-Based Target Detection Facilitated by a 3-Stage G-Quadruplex Isothermal Exponential Amplification Reaction
03:38

Aptamer-Based Target Detection Facilitated by a 3-Stage G-Quadruplex Isothermal Exponential Amplification Reaction

Published on: October 6, 2022

2.0K

Related Experiment Videos

Last Updated: Apr 9, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.6K
Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.3K
Aptamer-Based Target Detection Facilitated by a 3-Stage G-Quadruplex Isothermal Exponential Amplification Reaction
03:38

Aptamer-Based Target Detection Facilitated by a 3-Stage G-Quadruplex Isothermal Exponential Amplification Reaction

Published on: October 6, 2022

2.0K

Area of Science:

  • Biotechnology
  • Nanomedicine
  • Pharmacology

Background:

  • Conventional Western medicine often lacks selectivity, leading to "off-target" side effects.
  • Targeted therapy enhances treatment selectivity and minimizes adverse effects.
  • Aptamers, or chemical antibodies, are emerging as effective targeting ligands for disease biomarkers.

Purpose of the Study:

  • To review aptamer-drug conjugates (ApDCs) for targeted drug delivery.
  • To highlight the advantages of aptamers in developing targeted therapies.
  • To discuss the application of ApDCs in various therapeutic modalities, including cancer treatment.

Main Methods:

  • Review of current literature on aptamer-drug conjugates.
  • Analysis of aptamer characteristics for targeted delivery.
  • Exploration of ApDC applications in chemotherapy, gene therapy, immunotherapy, photodynamic therapy, and photothermal therapy.

Main Results:

  • Aptamers demonstrate unique features making them promising for targeted therapy.
  • ApDCs can significantly enhance the selectivity of therapeutic effects.
  • The review covers diverse applications of ApDCs, particularly in oncology.

Conclusions:

  • Aptamer-drug conjugates represent a promising strategy for targeted drug delivery.
  • ApDCs offer a pathway to improve therapeutic efficacy and reduce side effects.
  • Further development of ApDCs holds potential for advancing cancer treatment and other therapies.